CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect
The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involve...
Saved in:
Published in | Journal of experimental & clinical cancer research Vol. 42; no. 1; pp. 63 - 22 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
15.03.2023
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC.
In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored.
CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC.
CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC. |
---|---|
AbstractList | The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC.
In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored.
CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC.
CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC. BackgroundThe Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC.MethodsIn the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored.ResultsCircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC.ConclusionsCircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC. Abstract Background The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC. Methods In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored. Results CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC. Conclusions CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC. Background The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC. Methods In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored. Results CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC. Conclusions CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC. Keywords: Circular RNA, Hepatocellular carcinoma, The Warburg effect, Encoding capacity, miRNA sponge The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC. In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored. CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC. CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC. The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC.BACKGROUNDThe Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC) patients. An increasing body of literature suggests that circular RNAs (circRNAs) are important regulators for HCC. However, few circRNAs involved in the Warburg effect of HCC have hitherto been investigated. Herein, we aimed to explore the contribution of circFOXK2 to glucose metabolism reprogramming in HCC.In the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored.METHODSIn the present study, different primers were designed to identify 14 circRNAs originating from the FOXK2 gene, and their differential expression between HCC and adjacent liver tissues was screened. Ultimately, circFOXK2 (hsa_circ_0000817) was selected for further research. Next, the clinical significance of circFOXK2 was evaluated. We then assessed the pro-oncogenic activity of circFOXK2 and its impact on the Warburg effect in both HCC cell lines and animal xenografts. Finally, the molecular mechanisms of how circFOXK2 regulates the Warburg effect of HCC were explored.CircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC.RESULTSCircFOXK2 was aberrantly upregulated in HCC tissues and positively correlated with poor clinical outcomes in patients that underwent radical hepatectomy. Silencing of circFOXK2 significantly suppressed HCC progression both in vitro and in vivo. Mechanistically, circFOXK2 upregulated the expression of protein FOXK2-142aa to promote LDHA phosphorylation and led to mitochondrial fission by regulating the miR-484/Fis1 pathway, ultimately activating the Warburg effect in HCC.CircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC.CONCLUSIONSCircFOXK2 is a prognostic biomarker of HCC that promotes the Warburg effect by promoting the expression of proteins and miRNA sponges that lead to tumor progression. Overall, circFOXK2 has huge prospects as a potential therapeutic target for patients with HCC. |
ArticleNumber | 63 |
Audience | Academic |
Author | Cai, Jianye Sui, Xin Zhang, Qi Pan, Zihao Zheng, Kanghong Song, Wen Liu, Yubin Yang, Yang Zhang, Jiebin Chen, Guihua Xiao, Jiaqi Lu, Tongyu Li, Yang Liang, Jinliang Chen, Haitian Zheng, Jun Yan, Xijing |
Author_xml | – sequence: 1 givenname: Jun surname: Zheng fullname: Zheng, Jun – sequence: 2 givenname: Xijing surname: Yan fullname: Yan, Xijing – sequence: 3 givenname: Tongyu surname: Lu fullname: Lu, Tongyu – sequence: 4 givenname: Wen surname: Song fullname: Song, Wen – sequence: 5 givenname: Yang surname: Li fullname: Li, Yang – sequence: 6 givenname: Jinliang surname: Liang fullname: Liang, Jinliang – sequence: 7 givenname: Jiebin surname: Zhang fullname: Zhang, Jiebin – sequence: 8 givenname: Jianye surname: Cai fullname: Cai, Jianye – sequence: 9 givenname: Xin surname: Sui fullname: Sui, Xin – sequence: 10 givenname: Jiaqi surname: Xiao fullname: Xiao, Jiaqi – sequence: 11 givenname: Haitian surname: Chen fullname: Chen, Haitian – sequence: 12 givenname: Guihua surname: Chen fullname: Chen, Guihua – sequence: 13 givenname: Qi surname: Zhang fullname: Zhang, Qi – sequence: 14 givenname: Yubin surname: Liu fullname: Liu, Yubin – sequence: 15 givenname: Yang surname: Yang fullname: Yang, Yang – sequence: 16 givenname: Kanghong surname: Zheng fullname: Zheng, Kanghong – sequence: 17 givenname: Zihao surname: Pan fullname: Pan, Zihao |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36922872$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kk-P1CAYhxuzxv2jX8CDITExXroCBUpPZjNxdeMme9HojVAKHTYURqCbePOjS2fWdWZjDGmg8LwP7ZvfaXXkg9dV9RLBc4Q4e5dQAwmrIW7KwzCp0ZPqBLWU1V3H2NHe-rg6TekWQoY61D2rjhvWYcxbfFL9WtmoLm--f8ZgE8MUsk5grTcyB6Wdm52MQMmorA-TXIgx6pRs8ED6ATgthwRyAOUohEI6662Sbgv6kGwCd1aCqMciytaPIK81-CZjP8cRaGO0ys-rp0a6pF_cz2fV18sPX1af6uubj1eri-ta0Y7muumJMlTTXslW9Vg2yjBjGMVIDprppqgMoaynLTc9QgZxhbUZCO0HBIeBNmfV1c47BHkrNtFOMv4UQVqx3QhxFDJmq5wWmCHaG8YaDQ3hEHUdgZzA7bukHBXX-51rM_eTHpT2OUp3ID088XYtxnAnEISId4gVw9t7Qww_Zp2ymGxaOi69DnMSuOW87SjmpKCvH6G3YY6-9GpLEU4Jav5Soyx_YL0J5WK1SMVFSxBpEWWL6_wfVBmDnqwq6TK27B8UvNkrWGvp8joFN-cSgXQIvtpvyUMv_iStAHgHqBhSito8IAiKJc5iF2dR4iy2cRZLo_mjImWzXC4v323d_0p_A_zT-Z8 |
CitedBy_id | crossref_primary_10_1007_s10142_023_01096_y crossref_primary_10_1016_j_redox_2025_103556 crossref_primary_10_1038_s41420_024_02261_3 crossref_primary_10_1186_s13045_023_01452_2 crossref_primary_10_1186_s12935_023_03186_0 crossref_primary_10_1186_s12943_024_02101_z crossref_primary_10_1016_j_drup_2024_101097 crossref_primary_10_3390_biomedicines13010160 crossref_primary_10_3748_wjg_v31_i11_102848 crossref_primary_10_1038_s12276_025_01413_4 crossref_primary_10_1002_mco2_70055 crossref_primary_10_1016_j_cellsig_2024_111243 crossref_primary_10_1016_j_gendis_2024_101347 crossref_primary_10_1016_j_bcp_2024_116419 crossref_primary_10_3892_ijo_2024_5637 crossref_primary_10_1021_cbmi_4c00105 |
Cites_doi | 10.1016/j.jhep.2018.01.012 10.1002/path.4525 10.1016/j.biocel.2017.05.019 10.1038/s41586-019-0900-5 10.1016/j.cell.2018.12.021 10.1038/nbt.2890 10.1186/s12943-020-1147-3 10.1038/s41576-019-0158-7 10.1186/s12943-020-01179-5 10.1056/NEJMra1001683 10.7150/thno.33758 10.1002/hep.30795 10.1158/1078-0432.CCR-19-0674 10.1158/1078-0432.CCR-13-0304 10.1002/ijc.31278 10.1158/0008-5472.CAN-21-1259 10.1002/hep.30666 10.1002/advs.201900949 10.1126/science.1160809 10.3322/caac.21492 10.1186/s12943-018-0909-7 10.1002/hep.30671 10.1016/j.cell.2011.07.014 10.1080/15476286.2015.1020271 10.1186/s12943-019-1129-5 10.1016/j.cell.2016.07.035 10.1038/onc.2017.6 10.1186/s12943-019-1046-7 10.1038/ncomms15308 10.1038/emboj.2013.53 10.1158/0008-5472.CAN-19-3268 10.1038/s41419-020-2424-1 10.1186/s12943-020-1135-7 10.7150/thno.31716 10.1186/s12943-019-1086-z 10.1016/j.ccell.2016.09.010 10.1002/hep.31068 10.1002/hep.29462 10.1002/hep.30793 10.1186/s12943-019-1031-1 10.2147/OTT.S157126 10.1016/j.molcel.2014.08.019 10.1016/S0140-6736(03)14964-1 10.1038/nature11928 10.1186/s12935-017-0407-9 10.1002/1878-0261.12424 10.1016/j.cmet.2018.10.011 10.1016/j.ymthe.2021.08.027 10.1016/j.canlet.2019.10.029 |
ContentType | Journal Article |
Copyright | 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
Copyright_xml | – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s13046-023-02624-1 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central Database Suite (ProQuest) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1756-9966 |
EndPage | 22 |
ExternalDocumentID | oai_doaj_org_article_2615bf663e0f4801994084063e0fa581 PMC10018916 A741471564 36922872 10_1186_s13046_023_02624_1 |
Genre | Journal Article |
GeographicLocations | Massachusetts China Germany United States--US |
GeographicLocations_xml | – name: China – name: Massachusetts – name: Germany – name: United States--US |
GrantInformation_xml | – fundername: Natural Science Foundation of China grantid: 81901943 – fundername: Guangdong Basic and Applied Basic Research Foundation grantid: 2021A1515111058 – fundername: Natural Science Foundation of Guangdong Province grantid: 2021A1515012136 – fundername: National Natural Science Foundation of China grantid: 82170631 – fundername: Natural Science Foundation of Guangdong Province grantid: 2021A1515010571 – fundername: National Natural Science Foundation of China grantid: 82073171 – fundername: Guangdong Key Laboratory of Liver Disease Research grantid: 2020B1212060019 – fundername: Natural Science Foundation of Guangdong Province grantid: 2021A1515011156 – fundername: National 13th Five-Year Science and Technology Plan Major Projects of China grantid: 2017ZX10203205 – fundername: National key research and development program grantid: 2017YFA0104304 – fundername: ; grantid: 202102020237 – fundername: ; – fundername: ; grantid: 201803040005 – fundername: ; grantid: 2019A1515011698; 2021A1515012136; 2021A1515011156; 2021A1515010571 – fundername: ; grantid: 2020B1212060019 – fundername: ; grantid: WW201905 – fundername: ; grantid: 82073171; 81900597; 81802897; 81770648; 81970567; 82100693; 82170631; 81972286 – fundername: ; grantid: P02093; P02095 – fundername: ; grantid: WW201701 – fundername: ; grantid: 2021A1515111058 |
GroupedDBID | --- 0R~ 29K 2WC 4.4 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 D-I DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP ~8M CGR CUY CVF ECM EIF NPM PMFND 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c595t-3b4cf5e5bca7cb2a3cf6ff6521ade6e3fecf456b578fb11f18c2efd45bd10dd53 |
IEDL.DBID | 7X7 |
ISSN | 1756-9966 0392-9078 |
IngestDate | Wed Aug 27 01:21:23 EDT 2025 Thu Aug 21 18:37:30 EDT 2025 Fri Jul 11 03:48:17 EDT 2025 Fri Jul 25 06:11:25 EDT 2025 Tue Jun 17 21:18:43 EDT 2025 Tue Jun 10 20:42:41 EDT 2025 Thu May 22 21:19:42 EDT 2025 Thu Apr 03 07:01:42 EDT 2025 Tue Jul 01 02:26:49 EDT 2025 Thu Apr 24 22:57:24 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | The Warburg effect miRNA sponge Circular RNA Hepatocellular carcinoma Encoding capacity |
Language | English |
License | 2023. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c595t-3b4cf5e5bca7cb2a3cf6ff6521ade6e3fecf456b578fb11f18c2efd45bd10dd53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/2788485413?pq-origsite=%requestingapplication% |
PMID | 36922872 |
PQID | 2788485413 |
PQPubID | 105475 |
PageCount | 22 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_2615bf663e0f4801994084063e0fa581 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10018916 proquest_miscellaneous_2788795284 proquest_journals_2788485413 gale_infotracmisc_A741471564 gale_infotracacademiconefile_A741471564 gale_healthsolutions_A741471564 pubmed_primary_36922872 crossref_primary_10_1186_s13046_023_02624_1 crossref_citationtrail_10_1186_s13046_023_02624_1 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-03-15 |
PublicationDateYYYYMMDD | 2023-03-15 |
PublicationDate_xml | – month: 03 year: 2023 text: 2023-03-15 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of experimental & clinical cancer research |
PublicationTitleAlternate | J Exp Clin Cancer Res |
PublicationYear | 2023 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | JN Vo (2624_CR5) 2019; 176 F Bray (2624_CR1) 2018; 68 Y Su (2624_CR25) 2020; 19 J Guarnerio (2624_CR7) 2016; 166 S Memczak (2624_CR9) 2013; 495 P Wu (2624_CR39) 2020; 19 J Li (2624_CR44) 2022; 82 L Jin (2624_CR31) 2017; 36 Y Wei (2624_CR16) 2020; 71 B Wang (2624_CR36) 2018; 11 H Wang (2624_CR14) 2018; 17 SM Sanderson (2624_CR21) 2018; 28 V Sukonina (2624_CR23) 2019; 566 L Salmena (2624_CR42) 2011; 146 Y Hu (2624_CR45) 2017; 17 F Du (2624_CR35) 2019; 9 J Yu (2624_CR17) 2018; 68 J Zheng (2624_CR28) 2020; 11 ZQ Hu (2624_CR12) 2020; 72 Z Pan (2624_CR10) 2020; 19 WM Linehan (2624_CR32) 2013; 19 YH Lin (2624_CR19) 2018; 67 L Wang (2624_CR15) 2019; 18 WR Jeck (2624_CR8) 2014; 32 LL Chen (2624_CR4) 2015; 12 Q Li (2624_CR13) 2019; 70 T Gao (2624_CR48) 2020; 469 C Hage (2624_CR26) 2019; 70 G Qin (2624_CR27) 2020; 71 F Zhang (2624_CR37) 2018; 142 JM Llovet (2624_CR2) 2003; 362 L Qiu (2624_CR34) 2019; 13 Y Ji (2624_CR40) 2017; 8 R Ashwal-Fluss (2624_CR6) 2014; 56 N Li (2624_CR47) 2020; 26 CH Wong (2624_CR38) 2020; 80 2624_CR29 PF Zhang (2624_CR18) 2019; 18 L Shan (2624_CR22) 2016; 30 MG Vander Heiden (2624_CR20) 2009; 324 M Lei (2624_CR30) 2020; 19 Q Mei (2624_CR46) 2015; 236 LS Kristensen (2624_CR33) 2019; 20 P Li (2624_CR43) 2022; 30 HB El-Serag (2624_CR3) 2011; 365 MF Lin (2624_CR24) 2017; 88 L Wei (2624_CR41) 2019; 18 L Chen (2624_CR11) 2020; 7 J Hagenbuchner (2624_CR49) 2019; 9 |
References_xml | – volume: 68 start-page: 1214 issue: 6 year: 2018 ident: 2624_CR17 publication-title: J Hepatol doi: 10.1016/j.jhep.2018.01.012 – volume: 236 start-page: 165 issue: 2 year: 2015 ident: 2624_CR46 publication-title: J Pathol doi: 10.1002/path.4525 – volume: 88 start-page: 155 year: 2017 ident: 2624_CR24 publication-title: Int J Biochem Cell Biol doi: 10.1016/j.biocel.2017.05.019 – volume: 566 start-page: 279 issue: 7743 year: 2019 ident: 2624_CR23 publication-title: Nature doi: 10.1038/s41586-019-0900-5 – volume: 176 start-page: 869 issue: 4 year: 2019 ident: 2624_CR5 publication-title: Cell doi: 10.1016/j.cell.2018.12.021 – volume: 32 start-page: 453 issue: 5 year: 2014 ident: 2624_CR8 publication-title: Nat Biotechnol doi: 10.1038/nbt.2890 – volume: 19 start-page: 22 issue: 1 year: 2020 ident: 2624_CR39 publication-title: Mol Cancer doi: 10.1186/s12943-020-1147-3 – volume: 20 start-page: 675 issue: 11 year: 2019 ident: 2624_CR33 publication-title: Nat Rev Genet doi: 10.1038/s41576-019-0158-7 – volume: 19 start-page: 71 issue: 1 year: 2020 ident: 2624_CR10 publication-title: Mol Cancer doi: 10.1186/s12943-020-01179-5 – volume: 365 start-page: 1118 issue: 12 year: 2011 ident: 2624_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMra1001683 – volume: 9 start-page: 4909 issue: 17 year: 2019 ident: 2624_CR49 publication-title: Theranostics doi: 10.7150/thno.33758 – volume: 71 start-page: 130 issue: 1 year: 2020 ident: 2624_CR16 publication-title: Hepatology doi: 10.1002/hep.30795 – volume: 26 start-page: 1736 issue: 7 year: 2020 ident: 2624_CR47 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-0674 – volume: 19 start-page: 3345 issue: 13 year: 2013 ident: 2624_CR32 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-0304 – volume: 142 start-page: 2543 issue: 12 year: 2018 ident: 2624_CR37 publication-title: Int J Cancer doi: 10.1002/ijc.31278 – volume: 82 start-page: 1055 issue: 6 year: 2022 ident: 2624_CR44 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-21-1259 – volume: 70 start-page: 1280 issue: 4 year: 2019 ident: 2624_CR26 publication-title: Hepatology doi: 10.1002/hep.30666 – volume: 7 start-page: 1900949 issue: 4 year: 2020 ident: 2624_CR11 publication-title: Adv Sci (Weinh) doi: 10.1002/advs.201900949 – volume: 324 start-page: 1029 issue: 5930 year: 2009 ident: 2624_CR20 publication-title: Science doi: 10.1126/science.1160809 – volume: 68 start-page: 394 issue: 6 year: 2018 ident: 2624_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21492 – volume: 17 start-page: 165 issue: 1 year: 2018 ident: 2624_CR14 publication-title: Mol Cancer doi: 10.1186/s12943-018-0909-7 – volume: 70 start-page: 1298 issue: 4 year: 2019 ident: 2624_CR13 publication-title: Hepatology doi: 10.1002/hep.30671 – volume: 146 start-page: 353 issue: 3 year: 2011 ident: 2624_CR42 publication-title: Cell doi: 10.1016/j.cell.2011.07.014 – volume: 12 start-page: 381 issue: 4 year: 2015 ident: 2624_CR4 publication-title: RNA Biol doi: 10.1080/15476286.2015.1020271 – volume: 19 start-page: 23 issue: 1 year: 2020 ident: 2624_CR25 publication-title: Mol Cancer doi: 10.1186/s12943-019-1129-5 – volume: 166 start-page: 1055 issue: 4 year: 2016 ident: 2624_CR7 publication-title: Cell doi: 10.1016/j.cell.2016.07.035 – volume: 36 start-page: 3797 issue: 27 year: 2017 ident: 2624_CR31 publication-title: Oncogene doi: 10.1038/onc.2017.6 – volume: 18 start-page: 119 issue: 1 year: 2019 ident: 2624_CR15 publication-title: Mol Cancer doi: 10.1186/s12943-019-1046-7 – volume: 8 start-page: 15308 year: 2017 ident: 2624_CR40 publication-title: Nat Commun doi: 10.1038/ncomms15308 – ident: 2624_CR29 doi: 10.1038/emboj.2013.53 – volume: 80 start-page: 2138 issue: 11 year: 2020 ident: 2624_CR38 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-19-3268 – volume: 11 start-page: 256 issue: 4 year: 2020 ident: 2624_CR28 publication-title: Cell Death Dis doi: 10.1038/s41419-020-2424-1 – volume: 19 start-page: 30 issue: 1 year: 2020 ident: 2624_CR30 publication-title: Mol Cancer doi: 10.1186/s12943-020-1135-7 – volume: 9 start-page: 3879 issue: 13 year: 2019 ident: 2624_CR35 publication-title: Theranostics doi: 10.7150/thno.31716 – volume: 18 start-page: 147 issue: 1 year: 2019 ident: 2624_CR41 publication-title: Mol Cancer doi: 10.1186/s12943-019-1086-z – volume: 30 start-page: 708 issue: 5 year: 2016 ident: 2624_CR22 publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.09.010 – volume: 72 start-page: 906 issue: 3 year: 2020 ident: 2624_CR12 publication-title: Hepatology doi: 10.1002/hep.31068 – volume: 67 start-page: 188 issue: 1 year: 2018 ident: 2624_CR19 publication-title: Hepatology doi: 10.1002/hep.29462 – volume: 71 start-page: 112 issue: 1 year: 2020 ident: 2624_CR27 publication-title: Hepatology doi: 10.1002/hep.30793 – volume: 18 start-page: 105 issue: 1 year: 2019 ident: 2624_CR18 publication-title: Mol Cancer doi: 10.1186/s12943-019-1031-1 – volume: 11 start-page: 1067 year: 2018 ident: 2624_CR36 publication-title: Onco Targets Ther doi: 10.2147/OTT.S157126 – volume: 56 start-page: 55 issue: 1 year: 2014 ident: 2624_CR6 publication-title: Mol Cell doi: 10.1016/j.molcel.2014.08.019 – volume: 362 start-page: 1907 issue: 9399 year: 2003 ident: 2624_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(03)14964-1 – volume: 495 start-page: 333 issue: 7441 year: 2013 ident: 2624_CR9 publication-title: Nature doi: 10.1038/nature11928 – volume: 17 start-page: 36 year: 2017 ident: 2624_CR45 publication-title: Cancer Cell Int doi: 10.1186/s12935-017-0407-9 – volume: 13 start-page: 441 issue: 2 year: 2019 ident: 2624_CR34 publication-title: Mol Oncol doi: 10.1002/1878-0261.12424 – volume: 28 start-page: 669 issue: 5 year: 2018 ident: 2624_CR21 publication-title: Cell Metab doi: 10.1016/j.cmet.2018.10.011 – volume: 30 start-page: 431 issue: 1 year: 2022 ident: 2624_CR43 publication-title: Mol Ther doi: 10.1016/j.ymthe.2021.08.027 – volume: 469 start-page: 89 year: 2020 ident: 2624_CR48 publication-title: Cancer Lett doi: 10.1016/j.canlet.2019.10.029 |
SSID | ssj0061919 |
Score | 2.445102 |
Snippet | The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma (HCC)... Background The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma... BackgroundThe Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular carcinoma... Abstract Background The Warburg effect is well-established to be essential for tumor progression and accounts for the poor clinical outcomes of hepatocellular... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 63 |
SubjectTerms | Animals Apoptosis Cancer therapies Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - pathology Cell Line, Tumor Cell Proliferation - genetics Circular RNA Dehydrogenases Development and progression Encoding capacity Flow cytometry Gene expression Gene Expression Regulation, Neoplastic Glucose metabolism Hepatocellular carcinoma Hepatoma Humans Hybridization Kinases Liver Liver cancer Liver Neoplasms - genetics Liver Neoplasms - pathology Medical prognosis MicroRNAs MicroRNAs - genetics MicroRNAs - metabolism miRNA sponge Phosphorylation Physiological aspects Prognosis Proteins RNA RNA, Circular - genetics The Warburg effect |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gFCMhcUBW147tjY9txaoCFS5U7M3yk65UkmqTcuanM7az0UZIcOGwh6zHUjIPf98k4zFCb4ER8EiNAeZmHOE2OmIldcQDmgMAgcfk2pyLz_L8kn9ci_XeUV-pJqy0By6KOwaGL2wEXAyLmFqdKMUXkJTkayPypmsGmLdLpsoaDFkBVbstMo087mn6AEgAn-AnGSd0BkO5W_-fa_IeKM0LJvcQaPUA3R-pIz4pt_wQ3QntI3T3Yvw4_hj9Otts3erL-hPDN7nILvT4CtBm6NLb-VRuil06Oajtfhic67JKTw5sWo-vwdY9HjoMQ10HkuOOySzYdv2mxz83Bm_L0fWAdxiYI_5mklG-41IV8gRdrj58PTsn4wELxAklBlJb7qIIwjqzdJaZ2kUZowRENz7IUMPUCATLQlRHS2mkjWMhei6spwvvRf0UHbRdG54j7E3k3jseFt5yEZVZAjNUMgTFozVcVIju9K3d2H08HYJxrXMW0khdbKTBRjrbSNMKvZ_m3JTeG3-VPk1mnCRT3-z8B3iTHr1J_8ubKvQ6OYEum1Cn6NcnQLwAxoXkFXqXJVL8wwM4M25jADWkTlozycOZJMStmw_vHE2P60av2bJpeCOAWVTozTScZqZauDZ0t0VmqQTwigo9K345PXQtFYMcmFWomXnsTCvzkXZzlbuKp2ZcDSQLL_6HHl-ieyxHW02oOEQHw_Y2vAL2NtijHKi_AVrKQQI priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELaqIiEuiDeBAkZC4oAM68R2kgNCpWJVgRYurNib5We70jYpSYrgxk9n7DzUiKqHPex6HCWemXzfrMczCL0CRsA8VQqYmzKEaW-IFtQQC2gOAAQWE3NzVl_F8Zp93vDNHhrbHQ0L2F4Z2oV-Uutm9_b3zz8fwOHfR4cvxLuWhu09AugDH5EyAtHQDUCmPDjqik27ChArxEYfgJiCBJ4_HqK58hozoIr1_P9_a1-CrXlK5SWMWt5BtwdyiQ97a7iL9lx1D91cDdvn99Hfo21jlt82X1J8HtPwXItPAY-6Ovx_HxJSsQm9har6TOGYudVX7cCqsngH1tDirsYwVNcgOZypjIJV3W5b_GurcNM3twdExMAt8Q8V1HaC-7yRB2i9_PT96JgMLRiI4SXvSKaZ8dxxbVRudKoy44X3AjBfWSdcBlM9UDANfu81pZ4WJnXeMq4tXVjLs4dov6or9xhhqzyz1jC3sJpxX6ocuGMpnCuZ14rxBNFxvaUZ6pOHNhk7GeOUQsheRxJ0JKOOJE3Qm2nOeV-d41rpj0GNk2SorB1_qJsTOTiqhIiSaw88zC18KK1TlmwBQXD8rngBF3kRjED2x1Sn94M8BGoGQM8FS9DrKBFsFh7AqOGgAyxDqLU1kzyYSYJnm_nwaGhydAyZ5kXBCg7cI0Evp-EwM2TLVa6-6GXykgPzSNCj3i6nh85EmUKUnCaomFnsbFXmI9X2NNYdD-W6Cggnnlx_X0_RrTT6UUYoP0D7XXPhngFz6_Tz6I7_ALdsP14 priority: 102 providerName: Scholars Portal |
Title | CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36922872 https://www.proquest.com/docview/2788485413 https://www.proquest.com/docview/2788795284 https://pubmed.ncbi.nlm.nih.gov/PMC10018916 https://doaj.org/article/2615bf663e0f4801994084063e0fa581 |
Volume | 42 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MvY99z22UaDPYwRCNbUuyn0ZSGspFulJWFvQh9toHOzuJ0z_vTd5IVr2bQBxscnUysO93vTjrdIfQOLALmqVJguSlDmPaGaEENsYDmAEAgMTE2Z34mTi_YpwVfpAW3NoVVbnViVNS2MWGN_DAHX42VHHTux9UvEqpGhd3VVELjPtoNqctCSNdk0Ttc4BvEwh6AkIIEu357aKYUhy0NW4IEEAsukTNCB8AU8_f_r6VvwdQwhPIWJs0eo0fJmMRHHfefoHuufooezNN2-TP053i5NrMvi885XsWwO9fiK8CfTRPW60MAKjahllDd_FQ4Rmp1WTqwqi2-Bu63eNNgaGoaoExnKCNh3bTLFv9eKrzuitkDAmKwJfF3Fdh0ibs4kefoYnby7fiUpJILxPCKb0ihmfHccW3UxOhcFcYL7wVgvLJOuAK6ejC5NMxzryn1tDS585ZxbenYWl68QDt1U7tXCFvlmbWGubHVjPtKTcBWrIRzFfNaMZ4huh1vaVI-8lAW41pGv6QUsuORBB7JyCNJM_Sh77PqsnHcST0NbOwpQybt-EOzvpRpYkrwILn2YHe5sQ-pdKqKjcHpjc-Kl_CSN0EIZHcstdcH8ghMMQB2LliG3keKoBHgA4xKBxtgGEJurQHlwYASZrIZNm8FTSZN0sp_cp-ht31z6Bmi42rX3HQ0k4qDpZGhl51c9h9diCoHrzjPUDmQ2MGoDFvq5VXMMx7Sc5XgPuzd_b_20cM8zqOCUH6AdjbrG_caLLWNHsXpOEK705Ozr-ejuN4B9zkr4X4-_fEXSulAwg |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemTgJeEN8EBjMSiAcUrU5sN3lAaBurOroWhDaxN-PPrtJIStOBeOMv4m_k7CRlEdLe9tCH1Jeo8Z1_97v6fIfQS2AE1BEpgblJHVPldKw40bEBbw4OCCwm5OZMpnx0Qj-cstMN9Kc9C-PTKltMDEBtSu3_I99JIFajGQPMfbf4HvuuUX53tW2hUZvF2P76CSFb9fbwPej3VZIMD473R3HTVSDWLGerOFVUO2aZ0nKgVSJT7bhzHNyYNJbb1FntgFUoMGWnCHEk04l1hjJlSN8Y3yUCIH-TphDK9NDm3sH00-cW-yEaCa1EwCfz2EcS7TGdjO9UxG9CxuAj4cMTGpOOKwwdA_73C5ccYzdp85IXHN5Btxv6indre7uLNmxxD92YNBv099Hv_flSDz-ejhO8CIl-tsJn4PFWpd8h8CmvWPvuRUX5TeKQG1bXBcGyMPgc7K3CqxLDUFmCZHNqMwgWZTWv8I-5xEs7Cz3HihkG9oq_SG8YM1xnpjxAJ9eijoeoV5SFfYywkY4ao6ntG0WZy-UA2GnOrc2pU5KyCJF2voVuKqD7RhznIkRCGRe1jgToSAQdCRKhN-t7FnX9jyul97wa15K-dnf4olzORAMFAmJWphwwPdt3vnhPntM-hNnhWrIMHrLtjUDUB2HXCCR2gfwBlWCcRuh1kPAYBC-gZXOUAqbBV_PqSG51JAE7dHe4NTTRYFcl_q20CL1YD_s7fT5eYcuLWmaQM-A2EXpU2-X6pVOeJxCHJxHKOhbbmZXuSDE_C5XNfUGwDAKWJ1f_rm10c3Q8ORJHh9PxU3QrCWsqjQnbQr3V8sI-A564Us-bxYnR1-vGg7_P8n4N |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CircFOXK2+promotes+hepatocellular+carcinoma+progression+and+leads+to+a+poor+clinical+prognosis+via+regulating+the+Warburg+effect&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Zheng%2C+Jun&rft.au=Xijing+Yan&rft.au=Lu%2C+Tongyu&rft.au=Song%2C+Wen&rft.date=2023-03-15&rft.pub=BioMed+Central&rft.issn=1756-9966&rft.volume=42&rft.spage=1&rft_id=info:doi/10.1186%2Fs13046-023-02624-1 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |